Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Moleculin Biotech stock | 0.73

Own Moleculin Biotech stock in just a few minutes.

Posted

Fact checked

Moleculin Biotech, Inc is a biotechnology business based in the US. Moleculin Biotech shares (MBRX) are listed on the NASDAQ and all prices are listed in US Dollars. Moleculin Biotech employs 11 staff and has a market cap (total outstanding shares value) of USD$50.6 million.

How to buy shares in Moleculin Biotech

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Moleculin Biotech. Find the stock by name or ticker symbol: MBRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Moleculin Biotech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.73, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Moleculin Biotech, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Moleculin Biotech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Moleculin Biotech share price

Use our graph to track the performance of MBRX stocks over time.

Moleculin Biotech shares at a glance

Information last updated 2020-11-19.
Latest market close USD$0.73
52-week range USD$0.323 - USD$1.55
50-day moving average USD$0.7665
200-day moving average USD$0.9358
Wall St. target price USD$3.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.32

Buy Moleculin Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Moleculin Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Moleculin Biotech price performance over time

Historical closes compared with the close of $0.73 from 2020-11-16

1 week (2020-11-18) -5.19%
1 month (2020-10-23) -4.45%
3 months (2020-08-25) -17.98%
6 months (2020-05-22) N/A
1 year (2019-11-25) -29.81%
2 years (2018-11-23) -46.72%
3 years (2017-11-24) -58.29%
5 years (2015-11-22) N/A

Moleculin Biotech financials

Gross profit TTM USD$0
Return on assets TTM -45.75%
Return on equity TTM -110.72%
Profit margin 0%
Book value $0.234
Market capitalisation USD$50.6 million

TTM: trailing 12 months

Shorting Moleculin Biotech shares

There are currently 2.6 million Moleculin Biotech shares held short by investors – that's known as Moleculin Biotech's "short interest". This figure is 11.3% down from 2.9 million last month.

There are a few different ways that this level of interest in shorting Moleculin Biotech shares can be evaluated.

Moleculin Biotech's "short interest ratio" (SIR)

Moleculin Biotech's "short interest ratio" (SIR) is the quantity of Moleculin Biotech shares currently shorted divided by the average quantity of Moleculin Biotech shares traded daily (recently around 404352.72161742). Moleculin Biotech's SIR currently stands at 6.43. In other words for every 100,000 Moleculin Biotech shares traded daily on the market, roughly 6430 shares are currently held short.

However Moleculin Biotech's short interest can also be evaluated against the total number of Moleculin Biotech shares, or, against the total number of tradable Moleculin Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moleculin Biotech's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Moleculin Biotech shares in existence, roughly 40 shares are currently held short) or 0.0475% of the tradable shares (for every 100,000 tradable Moleculin Biotech shares, roughly 48 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Moleculin Biotech.

Find out more about how you can short Moleculin Biotech stock.

Moleculin Biotech share dividends

We're not expecting Moleculin Biotech to pay a dividend over the next 12 months.

Moleculin Biotech share price volatility

Over the last 12 months, Moleculin Biotech's shares have ranged in value from as little as $0.323 up to $1.55. A popular way to gauge a stock's volatility is its "beta".

MBRX.US volatility(beta: 2.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moleculin Biotech's is 2.1975. This would suggest that Moleculin Biotech's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Moleculin Biotech overview

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. The company has partnerships and collaboration agreement with The University of Texas MD Anderson Cancer Center, Emory University, Mayo Clinic Research Endeavor, The University of Iowa, Medical University of Gdansk, University of Bergen, DERMIN Sp. z o. o., and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site